Table 5 Association between GSTM1 and GSTP1 polymorphisms and clinicopathological features
From: The prognostic impact of GSTM1/GSTP1 genetic variants in bladder Cancer
| Â | GSTM1 | Â | GSTP1 | Â | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Null | Present | Â | AA | AG/GG | Â | ||||||
N | % | N | % | P value | N | % | N | % | P value | ||
Group age (Years) | ≤60 | 17 | 18.2% | 20 | 21.5% | 0.51 | 16 | 17.2% | 16 | 17.2% | 0.49 |
> 60 | 27 | 29.0% | 24 | 25.8% | 19 | 20.4% | 26 | 27.9% | |||
Gender | Male | 37 | 39.7% | 37 | 39.7% | 0.81 | 32 | 34.4% | 33 | 35.4% | 0.22 |
Female | 7 | 7.5% | 8 | 8.6% | 4 | 4.3% | 9 | 9.6% | |||
Race | Asian | 35 | 37.6% | 40 | 43.0% | 0.32 | 31 | 33.3% | 38 | 40.8% | 0.54 |
African | 8 | 8.6% | 5 | 5.3% | 5 | 5.3% | 4 | 4.3% | |||
Tumor Grade | High Grade | 29 | 31.1% | 26 | 27.9% | 0.18 | 23 | 24.7% | 26 | 27.9% | 0.67 |
Low Grade | 10 | 10.7% | 17 | 18.2% | 12 | 12.9% | 11 | 11.8% | |||
Cancer Type | MIBC | 28 | 30.1% | 23 | 24.7% | 0.17 | 18 | 19.3% | 21 | 22.5% | 1.00 |
NMIBC | 10 | 10.7% | 16 | 17.2% | 12 | 12.9% | 14 | 15.0% | |||
Subtypes | Transitional | 32 | 34.4% | 39 | 41.9% | 0.08 | 30 | 32.2% | 35 | 37.6% | 0.23 |
Squamous | 3 | 3.2% | 0 | 0.0% | 0 | 0.0% | 3 | 3.2% | |||
Transitional/ Squamous | 9 | 9.6% | 5 | 5.3% | 5 | 5.3% | 4 | 4.3% | |||
Lymph Node | Positive | 13 | 13.9% | 7 | 7.5% | 0.14 | 8 | 8.6% | 10 | 10.7% | 0.93 |
Negative | 30 | 32.2% | 35 | 37.6% | 26 | 27.9% | 31 | 33.3% | |||
Vascular Invasion | Positive | 10 | 10.7% | 7 | 7.5% | 0.41 | 6 | 6.4% | 9 | 9.6% | 0.60 |
Negative | 32 | 34.4% | 35 | 37.6% | 28 | 30.1% | 31 | 33.3% | |||
Metastasis | Positive | 11 | 11.8% | 9 | 9.6% | 0.60 | 7 | 7.5% | 13 | 13.9% | 0.27 |
Negative | 31 | 33.3% | 33 | 35.4% | 27 | 29.0% | 28 | 30.1% | |||
Survival | Alive | 26 | 27.9% | 37 | 39.7% | 0.01* | 29 | 31.1% | 26 | 27.9% | 0.072 |
Deceased | 18 | 19.3% | 8 | 8.6% | 7 | 7.5% | 16 | 17.2% | |||